Literature DB >> 20521166

Analysis of cure rate survival data under proportional odds model.

Yu Gu1, Debajyoti Sinha, Sudipto Banerjee.   

Abstract

Due to significant progress in cancer treatments and management in survival studies involving time to relapse (or death), we often need survival models with cured fraction to account for the subjects enjoying prolonged survival. Our article presents a new proportional odds survival models with a cured fraction using a special hierarchical structure of the latent factors activating cure. This new model has same important differences with classical proportional odds survival models and existing cure-rate survival models. We demonstrate the implementation of Bayesian data analysis using our model with data from the SEER (Surveillance Epidemiology and End Results) database of the National Cancer Institute. Particularly aimed at survival data with cured fraction, we present a novel Bayes method for model comparisons and assessments, and demonstrate our new tool's superior performance and advantages over competing tools.

Entities:  

Mesh:

Year:  2010        PMID: 20521166      PMCID: PMC2943572          DOI: 10.1007/s10985-010-9171-z

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  14 in total

1.  Estimation in a Cox proportional hazards cure model.

Authors:  J P Sy; J M Taylor
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

2.  Bayesian semiparametric models for survival data with a cure fraction.

Authors:  J G Ibrahim; M H Chen; D Sinha
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

3.  A semi-parametric accelerated failure time cure model.

Authors:  Chin-Shang Li; Jeremy M G Taylor
Journal:  Stat Med       Date:  2002-11-15       Impact factor: 2.373

4.  Modeling spatial survival data using semiparametric frailty models.

Authors:  Yi Li; Louise Ryan
Journal:  Biometrics       Date:  2002-06       Impact factor: 2.571

5.  Frailty modeling for spatially correlated survival data, with application to infant mortality in Minnesota.

Authors:  Sudipto Banerjee; Melanie M Wall; Bradley P Carlin
Journal:  Biostatistics       Date:  2003-01       Impact factor: 5.899

6.  Flexible Cure Rate Modeling Under Latent Activation Schemes.

Authors:  Freda Cooner; Sudipto Banerjee; Bradley P Carlin; Debajyoti Sinha
Journal:  J Am Stat Assoc       Date:  2007-06-01       Impact factor: 5.033

7.  The large sample distribution of the weighted log rank statistic under general local alternatives.

Authors:  M Ewell; J G Ibrahim
Journal:  Lifetime Data Anal       Date:  1997       Impact factor: 1.588

8.  A linear rank test for use when the main interest is in differences in cure rates.

Authors:  R J Gray; A A Tsiatis
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

9.  Parametric versus non-parametric methods for estimating cure rates based on censored survival data.

Authors:  Y u Yakovlev A
Journal:  Stat Med       Date:  1994-05-15       Impact factor: 2.373

10.  Improved models of tumour cure.

Authors:  S L Tucker; J M Taylor
Journal:  Int J Radiat Biol       Date:  1996-11       Impact factor: 2.694

View more
  4 in total

1.  Sample size calculation for the proportional hazards cure model.

Authors:  Songfeng Wang; Jiajia Zhang; Wenbin Lu
Journal:  Stat Med       Date:  2012-07-11       Impact factor: 2.373

2.  Computationally Efficient Estimation for the Generalized Odds Rate Mixture Cure Model with Interval-Censored Data.

Authors:  Jie Zhou; Jiajia Zhang; Wenbin Lu
Journal:  J Comput Graph Stat       Date:  2018-02-01       Impact factor: 2.302

3.  Time-to-event modeling of hypertension reveals the nonexistence of true controls.

Authors:  Daniel Shriner; Amy R Bentley; Jie Zhou; Kenneth Ekoru; Ayo P Doumatey; Guanjie Chen; Adebowale Adeyemo; Charles N Rotimi
Journal:  Elife       Date:  2020-12-01       Impact factor: 8.140

4.  Comparison Cure Rate Models by DIC Criteria in Breast Cancer Data

Authors:  Ahmad Reza Baghestani; Parviz Shahmirzalou; Soheila Sayad; Mohammad Esmaeil Akbari; Farid Zayeri
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.